CompletedPhase 2NCT05812781
A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome
Studying NLRP3-associated autoinflammatory disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Zomagen Biosciences Ltd.
- Principal Investigator
- Henrik Sonnergren, MD, PhDVentyx Biosciences, Inc
- Intervention
- VTX2735(drug)
- Enrollment
- 7 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2024
Study locations (2)
- Local Site # 222, San Diego, California, United States
- Local Site # 223, Columbus, Georgia, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05812781 on ClinicalTrials.govOther trials for NLRP3-associated autoinflammatory disease
Additional recruiting or active studies for the same condition.
See all trials for NLRP3-associated autoinflammatory disease →